Back to top

Analyst Blog

Gentiva Health Services Inc. (GTIV - Analyst Report) reported third-quarter 2012 operating net earnings of 32 cents per share, modestly beating the Zacks Consensus Estimate of 29 cents as well as year-ago quarter level of 27 cents per share. Operating net income of $9.9 million also compares favorably with $8.3 million in the year-ago quarter.

Including all one-time charges and results from discontinued operations, Gentiva posted net loss of $0.5 million or 2 cents per share, contracting substantially from the prior-year net loss of $473.8 million or $15.62 per share.

Gentiva’s net revenues declined 6% year over year to $424.4 million and also missed the Zacks Consensus Estimate of $428.0 million. The year-over-year decline was largely due to the sale and closure of some branches coupled with a 6% decline in the Home Health Episodic segment revenue to $206.4 million. This was followed by a year-over-year decline of 3% related to the Hospice segment revenue of $189.8 million.

Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) attributable to continuing operations increased 11.1% to $46.1 million from $41.5 million in the prior-year quarter.

Financial Update

Gentiva exited the quarter with cash and cash equivalents of approximately $156.0 million, down from $164.9 million as of December 31, 2011. Long-term debt was $938.1 million, down from $973.2 million at 2011 end.

During the reported quarter, net cash from operating activities amounted to $25.5 million versus a cash outflow of $5.5 million in the prior-year period. Free cash flow also improved considerably to $23.2 million from a negative $11.4 million in the third-quarter of 2011.

As of September 30, 2012, Gentiva had total assets of $1.48 billion and shareholders’ equity of $222.75 million, as compared with $1.53 billion and $202.5 million, respectively, as of December 31, 2011.

Outlook for 2012

Gentiva hiked its guidance for adjusted income from continuing operations to $1.20–$1.30 per share from $1.00–$1.20 guided earlier. Additionally, the guidance for net revenue was revised to $1.71–$1.74 billion from $1.70–$1.76 billion. However, the guidance does not include any impact of sequestration or Hurricane Sandy on the fourth quarter earnings.

Zacks Rank

Gentiva carries a Zacks #3 Rank, which translates into a short-term Hold rating. The company’s close competitor Amedisys Inc. (AMED - Analyst Report) also shares the Zacks #3 Rank, and is expected to release its third-quarter 2012 earnings before the market opens on November 6, 2012. According to the Zacks Consensus Estimate, Amedisys is expected to report operating earnings of 27 cents a share, falling 25.6% from its prior-year quarter earnings.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%